Neoprobe Corporation Stock Nyse
Equities
NEOP
US6405181065
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Jul. 03 | Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024 | CI |
Jun. 21 | Navidea Biopharmaceuticals, Inc. Announces Board Resignations | CI |
Financials (USD)
Sales 2021 | 532K | Sales 2022 | 65.65K | Capitalization | 6.78M |
---|---|---|---|---|---|
Net income 2021 | -11M | Net income 2022 | -15M | EV / Sales 2021 | 50.2 x |
Net cash position 2021 | 3.48M | Net Debt 2022 | 440K | EV / Sales 2022 | 110 x |
P/E ratio 2021 |
-2.5
x | P/E ratio 2022 |
-0.38
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 64.11% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Dais
DFI | Director of Finance/CFO | 58 | 23-07-27 |
Michael Blue
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Richard McFerron
LAW | General Counsel | - | 22-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joshua Wilson
BRD | Director/Board Member | 47 | 22-09-29 |
John Scott
BRD | Director/Board Member | 69 | 21-07-07 |
Jill Stefanelli
BRD | Director/Board Member | 46 | 23-05-31 |
1st Jan change | Capi. | |
---|---|---|
+16.59% | 44.44B | |
+41.02% | 39.84B | |
-10.62% | 37.68B | |
+29.92% | 31.46B | |
-9.23% | 27.02B | |
+12.34% | 26.29B | |
+41.53% | 13.8B | |
+31.49% | 12.46B | |
-7.40% | 11.26B |
- Stock Market
- Equities
- NAVB Stock
- NEOP Stock